Abstract
Ovarian cancer is the fourth leading cause of cancer deaths among U.S. women and has the highest fatality-to-case ratio of all gynecologic malignancies. It affects > 22,000 women and accounts for > 16,000 deaths every year with a projected 5 year mortality rate exceeding 70% (Jemal et al. 2007). This is, in part, due to the lack of early diagnosis, which makes it one of the most challenging of all cancers to fight. In fact, no observable or defined symptoms of disease are evident until it has metastasized. Therefore, there is a need to develop sensitive and reliable biomarker(s) for early detection, so that the high morbidity and deaths in ovarian cancer patients can be minimized. Current strategies for the detec-tion are based on biochemical markers, such as CA125, and biophysical markers assessed by ultrasound and/or Doppler imaging of the ovaries. The clinical utility of these strategies for early diagnosis, however, is limited due to the lack of specificity and sensitivity.
Mucins have emerged as markers of choice for disease diagnosis and prognosis owing to their aberrant expression in malignant cells and proven functional association of some mucins with the cancer development. To date, 20 human mucins have been identified and categorized into two classes (secreted/gel forming and membrane-bound) based on their structural characteristics and physiological fates (Hollingsworth and Swanson 2004; Singh et al. 2007). Mucins are produced by secretory epithelial cells for the lubrication and protection of ducts and lumen within the human body. However, mucins are also believed to play an important role in the pathogenesis of benign and malignant diseases of secretory epithelial cells (Hollingsworth and Swanson 2004). An aberrant expression of mucins has been reported in a variety of carcinomas. MUC4, which belongs to the membrane-bound mucin family, is aberrantly expressed in several types of carcinomas (Singh et al. 2007; Carraway et al. 2002; Chauhan et al. 2006). It is a multifunctional protein that is implicated in numerous cellular functions including cell adhesion, motility, signal transduction, tissue regeneration and differentiation, and tumor growth and metastasis. The diagnostic significance of MUC4 for ovarian carcinoma was recently evaluated in our laboratory by using immunohistochemical analysis of archival specimens (Chauhan et al. 2006). It was demonstrated that MUC4 could be a potential candidate marker for early diagnosis of epithelial ovarian carcinoma and can be utilized in combination with MUC16 to achieve greater sensitivity for the detection of late-stage tumors signifying the clinical applicability of MUC4 immunohistochemistry.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bhavanandan, V.P. (1991) Cancer-associated mucins and mucin-type glycoproteins. Glycobiology 1:493–503
Breedlove, G., and Busenhart, C. (2005) Screening and detection of ovarian cancer. J. Midwifery. Womens. Health. 50:51–54
Carraway, K.L., Perez, A., Idris, N., Jepson, S., Arango, M., Komatsu, M., Haq, B., Price-Schiavi, S.A., Zhang, J., and Carraway, C.A. (2002) Muc4/sialomucin complex., the intramembrane ErbB2 ligand, in cancer and epithelia: to protect. and to survive. Prog. Nucleic. Acid. Res. Mol. Biol. 71:149–185
Chaturvedi, P., Singh, A.P., Moniaux, N., Senapati, S., Chakraborty, S., Meza, J.L., and Batra, S.K. (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation., survival, and invasive properties. and interferes with. its interaction to extracellular matrix proteins. Mol. Cancer. Res. 5:309–320
Chaturvedi, P., Singh, A.P., Chakraborty, S., Chauhan, S.C., Bafna, S., Meza, J.L., Singh, P.K., Hollingsworth, M.A., Mehta, P.P., and Batra, S.K. (2008) MUC4 mucin interacts with. and stabilizes the. HER2 oncoprotein in human pancreatic cancer cells.Cancer. Res. 68(7):2065–2070
Chauhan, S.C., Singh, A.P., Ruiz, F., Johansson, S.L., Jain, M., Smith, L.M., Moniaux, N., and Batra, S.K. (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone. and in combination. with MUC1 and MUC16 (CA125). Mod. Pathol. 19:1386–1394
Escudero, F.M. (1999) [Conservative surgery in ovarian cancer]. An. R. Acad. Nac. Med. (Madr) 116:763–781
Giuntoli, R.L., Rodriguez, G.C., Whitaker, R.S., Dodge, R., and Voynow, J.A. (1998) Mucin gene expression in ovarian cancers. Cancer. Res. 58:5546–5550
Hakomori, S. (1989) Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer. Res. 52:257–331
Hayat, M.A. (2002) Microscopy, immunohistochemistry, and antigen retrival methods. Kluwer Academic/Springer, New York
Hayat, M.A. (ed) (2004–2006) Immunohistochemistry and in situ hybridization of human carconomas., vols 1–4. Elsevier/Academic, San Diego., CA
Hightower, R.D., Nguyen, H.N., Averette, H.E., Hoskins, W., Harrison, T., and Steren, A. (1994) National survey of ovarian carcinoma. IV: Patterns of care. and related survival. for older patients. Cancer 73:377–383
Hilkens, J., Ligtenberg, M.J., Vos, H.L., and Litvinov, S.V. (1992) Cell membrane-associated mucins. and their adhesion.-modulating property. Trends. Biochem. Sci. 17:359–363
Hollingsworth, M.A., and Swanson, B.J. (2004) Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer. 4:45–60
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007) Cancer statistics., 2007. CA Cancer. J. Clin. 57:43–66
Jhala, N., Jhala, D., Vickers, S.M., Eltoum, I., Batra, S.K., Manne, U., Eloubeidi, M., Jones, J.J., and Grizzle, W.E. (2006) Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am. J. Clin. Pathol. 126:572–579
Komatsu, M., Jepson, S., Arango, M.E., Carothers Carra-way, C.A., and Carraway, K.L. (2001) Muc4/sialomucin complex., an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth. and suppresses apoptosis. in a xenotransplanted tumor. Oncogene 20:461–470
Lopez-Ferrer, A., Alameda, F., Barranco, C., Garrido, M., and de, B.C. (2001) MUC4 expression is increased in dysplastic cervical disorders. Hum. Pathol. 32:1197–1202
McLemore, M.R., and Aouizerat, B. (2005) Introducing the MUC16 gene: implications for prevention. and early detection. in epithelial ovarian cancer. Biol. Res. Nurs. 6:262–267
Moniaux, N., Nollet, S., Porchet, N., Degand, P., Laine, A., and Aubert, J.P. (1999) Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem. J. 338:325–333
Nguyen, H.N., Averette, H.E., Hoskins, W., Sevin, B.U., Penalver, M., and Steren, A. (1993) National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gyneco-logy and Obstetrics staging system. Cancer 72:3007–3011
Nollet, S., Moniaux, N., Maury, J., Petitprez, D., Degand, P., Laine, A., Porchet, N., and Aubert, J.P. (1998) Human mucin gene MUC4: organization of its 5′-region and polymorphism of its central tandem repeat array. Biochem. J. 332:739–748
Ozols, R.F. (1990) Ovarian cancer. Semin. Surg. Oncol. 6:328–338
Park, H.U., Kim, J.W., Kim, G.E., Bae, H.I., Crawley, S.C., Yang, S.C., Gum, J.R Jr., Batra, S.K., Rousseau, K., Swallow, D.M., Sleisenger, M.H., and Kim, Y.S. (2003) Aberrant expression of MUC3 and MUC4 membrane-associated mucins. and sialyl Le.(x) antigen in pancreatic intraepithelial neoplasia. Pancreas 26:e48–e54
Ponnusamy, M.P., Singh, A.P., Jain, M., Chakraborty S., Moniaux, N., and Batra, S.K. (2008) MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br. J. Cancer. 99(3):520–6
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., and Miyajima, A. (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279:9190–9198
Singh, A.P., Moniaux, N., Chauhan, S.C., Meza, J.L., and Batra, S.K. (2004) Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer. Res. 64:622–630
Singh, A.P., Chaturvedi, P., and Batra, S.K. (2007) Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer. Res. 67:433–436
Swartz, M.J., Batra, S.K., Varshney, G.C., Hollingsworth, M.A., Yeo, C.J., Cameron, J.L., Wilentz, R.E., Hruban, R.H., and Argani, P. (2002) MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 117:791–796
Van, N.J Jr., Higgins, R.V., Donaldson, E.S., Gallion, H.H., Powell, D.E., Pavlik, E.J., Woods, C.H., and Thompson, E.A. (1990) Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer 65:573–577
Woolas, R.P., Xu, F.J., Jacobs, I.J., Yu, Y.H., Daly, L., Berchuck, A., Soper, JT., Clarke-Pearson, DL., Oram, D.H., Bast, R.C. Jr (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer. Inst. 85:1748–1751
Yin, B.W., Dnistrian, A., and Lloyd, K.O. (2002) Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int. J. Cancer. 98:737–740
Acknowledgements
The authors on this chapter were supported by a grant from Department of Defense OC040592 and the Olson Center for Women’s Health.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ponnusamy, M.P., Singh, A.P., Lele, S.M., Batra, S.K. (2010). Ovarian Carcinoma: Diagnostic Immunohistochemistry of MUCIN4 (MUC4). In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2918-8_2
Download citation
DOI: https://doi.org/10.1007/978-90-481-2918-8_2
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2917-1
Online ISBN: 978-90-481-2918-8
eBook Packages: MedicineMedicine (R0)